Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial

Simple summaryStereotactic body radiotherapy (SBRT) of 35–36.25 Gy in five fractions with the CyberKnife System yields excellent control with low toxicity in low–intermediate-risk prostate cancer patients. We found no differences in biochemical control and overall survival in relation to dose. There...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Frontiers in Oncology
المؤلفون الرئيسيون: Valentina Borzillo, Esmeralda Scipilliti, Donato Pezzulla, Marcello Serra, Gianluca Ametrano, Giuseppe Quarto, Sisto Perdonà, Sabrina Rossetti, Sandro Pignata, Anna Crispo, Piergiacomo Di Gennaro, Valentina D’Alesio, Cecilia Arrichiello, Francesca Buonanno, Simona Mercogliano, Antonio Russo, Antonio Tufano, Rossella Di Franco, Paolo Muto
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Frontiers Media S.A. 2023-11-01
الموضوعات:
clinical outcome
toxicity
low-and intermediate-risk
radiotherapy
prostate cancer
stereotactic body radiation
الوصول للمادة أونلاين:https://www.frontiersin.org/articles/10.3389/fonc.2023.1270498/full

الانترنت

https://www.frontiersin.org/articles/10.3389/fonc.2023.1270498/full

مواد مشابهة